Table 2 Neuroendocrine breast carcinomas compared to the prospective set of ductal carcinomas
NEBC (n = 39) | Ductal carcinomas (n = 506) | p-value | |
|---|---|---|---|
Median age at diagnosis | 66.0 | 57.0 | <0.0005 |
T class | 0.40 | ||
T1 | 28 (71.8%) | 322 (63.6%) | |
T2 | 9 (23.1%) | 167 (33.0%) | |
T3 | 2 (5.1%) | 12 (2.4%) | |
T4 | 0 (0.0%) | 5 (1.0%) | |
N class | 0.72 | ||
N0 | 23 (59.0%) | 314 (62.1%) | |
N1 | 10 (25.6%) | 149 (29.4%) | |
N2 | 5 (12.8%) | 41 (8.1%) | |
N3 | 0 (0.0%) | 2 (0.4%) | |
Missing | 1 (2.6%) | 0 (0.0%) | |
HER2 expression | 0.046 | ||
Negative | 37 (94.9%) | 437 (86.4%) | |
Positive | 1 (2.6%) | 69 (13.6%) | |
Missing | 1 (2.6%) | 0 (0.0%) | |
Estrogen receptor expression | 0.0062 | ||
Negative | 1 (2.6%) | 103 (20.4%) | |
Low | 0 (0.0%) | 18 (3.6%) | |
Moderate | 0 (0.0%) | 25 (4.9%) | |
High | 37 (94.9%) | 360 (71.1%) | |
Missing | 1 (2.6%) | 0 (0.0%) | |
Progesterone receptor expression | 0.088 | ||
Negative | 4 (10.3%) | 148 (29.2%) | |
Low | 4 (10.3%) | 61 (12.1%) | |
Moderate | 5 (12.8%) | 57 (11.3%) | |
High | 25 (61.5%) | 240 (47.4%) | |
Missing | 2 (5.1%) | 0 (0.0%) | |
Ki-67 | 0.060 | ||
Negative | 0 (0.0%) | 32 (6.3%) | |
Low | 14 (35.9%) | 217 (43.1%) | |
Moderate | 15 (38.5%) | 116 (23.0%) | |
High | 8 (20.5%) | 139 (27.6%) | |
Missing | 2 (5.1%) | 2 (0.4%) | |
Adjuvant radiotherapy | 0.23 | ||
No | 8 (20.5%) | 66 (13.4%) | |
Yes | 31 (79.5%) | 427 (86.6%) | |
Adjuvant chemotherapy | 0.00070 | ||
No | 27 (69.2%) | 207 (40.2%) | |
Yes | 12 (30.8%) | 299 (59.1%) | |
Adjuvant endocrine therapy | 0.015 | ||
No | 7 (17.9%) | 191 (37.7%) | |
Yes | 32 (82.1%) | 315 (62.3%) |